Biotech IPO freeze continues as second quarter is slowest in more than a decade July 4, 2022 Auto Bot BioPharma, biotech IPO, deals, News, Pharma 0 Summer weather is heating up but the market for IPOs remains cold. Bausch + Lomb’s successful return to the public markets in the second quarter proved to be an exception as the slowdown in IPO activity reached levels not seen in years.